ABSTRACT
Tumors pose a great threat to human health. As a systemic treatment, chemotherapy has held an unshakable position in tumor treatment. Chemotherapy induced nausea and vomiting (CINV) is a common adverse reaction during chemotherapy, which seriously affects patients' mood, quality of life and tumor control. The prevention and treatment of CINV is very important for cancer patients. As a more commonly used 5-HT3 receptor antagonist, tropisetron has a good clinical effect in the prevention and treatment of CINV. However, there are still some patients who do not have a good effect after using tropisetron. More and more studies indicated that these individual differences might be closely related to genetic polymorphisms. In order to provide ideas for clinical individualized medication under the guidance of gene polymorphisms, this article reviewed the influence of CYP2D6 gene polymorphisms on the effect of tropisetron in preventing CINV.